FrancophonIA/ELRC3.0 huggingface dataset:
English: In the primary double blind treatment phases of four phase III active-controlled clinical trials in patients with advanced malignancies involving bone, new primary malignancy was reported in 54/3691 (1.5%) of patients treated with XGEVA (median exposure of 13.8 months; range: 1.0-51.7) and 33/3688 (0.9%) of patients treated with zoledronic acid (median exposure of 12.9 months; range:
Danish: I de primære dobbeltblindede behandlingsfaser i fire aktivt-kontrollerede kliniske fase III-studier med patienter med fremskreden malignitet med involvering af knogle blev der rapporteret om nye primære maligniteter hos 54/3.691 (1,5 %) af patienterne, der blev behandlet med XGEVA (median eksponering 13,8 måneder; interval: 1,0-51,7) og 33/3.688 (0,9 %) af patienterne, der blev behandlet med zoledronsyre (median eksponering 12,9 måneder, interval: 1,0-50,8).
English: Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the RANKL/RANK interaction from occurring and resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer-induced bone destruction.
Danish: Denosumab er et humant monoklonalt antistof (IgG2), der er rettet mod og med høj affinitet og specificitet binder til RANKL og forhindrer RANKL/RANK-interaktionen.
English: • If you are under dental treatment or will undergo dental surgery (e.g. tooth extractions), inform your doctor about your dental treatment and tell your dentist that you are being treated with XGEVA.
Danish: • Fortæl det til din tandlæge, at du er i behandling med XGEVA, hvis du i øjeblikket får tandbehandling eller skal have en tandoperation (for eksempel udtrækning af tænder), og informér din læge om det.
English: Osteonecrosis of the external auditory canal3,4
Danish: Osteonekrose i ydre øregang3,4
English: Patients with prior history of ONJ or osteomyelitis of the jaw, an active dental or jaw condition requiring oral surgery, non-healed dental/oral surgery, or any planned invasive dental procedure were excluded from the clinical trials.
Danish: Patienter med ONJ eller osteomyelitis i kæben i anamnesen, en aktiv tand- eller kæbetilstand, hvor mundkirurgi var påkrævet, ikke-ophelet tand/mundoperation eller planlagt invasiv tandbehandling, var ekskluderet fra de kliniske studier.
English: Denosumab 120 mg Q4W Zoledronic Acid 4 mg Q4W
Danish: Denosumab 120 mg Q4W Zoledronsyre 4 mg Q4W
English: Each vial contains 120 mg of denosumab in 1.7 mL of solution (corresponding to 70 mg/mL).
Danish: Hvert hætteglas indeholder 120 mg denosumab i 1,7 ml injektionsvæske (svarende til 70 mg/ml).
English: Hypercalcaemia following treatment discontinuation in patients with giant cell tumour of bone3
Danish: Hyperkalcæmi efter seponering af behandlingen hos patienter med kæmpecelletumorer i knogle3
English: • persistent pain in the mouth and/or jaw, and/or swelling or non-healing of sores in the mouth or jaw, discharge, numbness or feeling of heaviness in the jaw, or loosening of a tooth could be signs of bone damage in the jaw (osteonecrosis).
Danish: • vedvarende smerter i munden og/eller kæben og/eller hævelse eller manglende opheling af sår i munden eller kæben, sekretion, følelsesløshed eller en følelse af tyngde i kæben eller en tand,
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Danish: Lægemidlet må kun udleveres efter ordination på en recept udstedet af en begrænset lægegruppe (se bilag I: Produktresumé; pkt.
English: In Study 6, XGEVA has been evaluated in a subset of 18 adolescent patients (aged 13-17 years) with giant cell tumour of bone who had reached skeletal maturity defined by at least 1 mature long bone (e.g. closed epiphyseal growth plate of the humerus) and body weight ≥ 45 kg. An objective response was observed for four of six evaluable adolescents in an interim analysis of Study 6.
Danish: Patienterne havde fuldt udviklet skelet, defineret som mindst 1 fuldt udviklet rørknogle (fx lukket vækstplade i en epifyse i humerus) og en legemsvægt på ≥ 45 kg. Der blev observeret en objektiv respons hos fire ud af seks evaluerbare unge patienter i en interimanalyse af studie 6.
English: Objective treatment response in patients with giant cell tumour of bone
Danish: Objektiv behandlingsrespons hos patienter med kæmpecelletumorer i knogle Antal patienter med evaluerbar respons
English: After treatment is discontinued, monitor patients for signs and symptoms of hypercalcaemia, consider periodic assessment of serum calcium and re-evaluate the patient's calcium and vitamin D supplementation requirements (see section 4.8).
Danish: Det skal overvejes at undersøge serumcalcium med jævne mellemrum og at vurdere patientens behov for tilskud af calcium og D-vitamin igen (se pkt.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/11/703/001 1 single use vial EU/1/11/703/002 4 single use vials EU/1/11/703/003 3 single use vials
Danish: MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/11/703/001 - 1 engangshætteglas
English: The solution may contain trace amounts of translucent to white proteinaceous particles.
Danish: Kan indeholde spormængder af gennemsigtige til hvide proteinlignende partikler.
English: XGEVA 120 mg solution for injection denosumab
Danish: XGEVA 120 mg injektionsvæske, opløsning denosumab
English: • excessive sweating,
Danish: • kraftig svedtendens,
English: What XGEVA contains
Danish: XGEVA indeholder:
English: First SRE Median time (months)
Danish: Første KRH Mediantid (mdr.)
English: XGEVA is not recommended in paediatric patients (age < 18) other than skeletally mature adolescents with giant cell tumour of bone (see section 4.4).
Danish: XGEVA anbefales ikke til børn (< 18 år), bortset fra knoglemæssigt fuldt udviklede unge med kæmpecelletumorer i knogle (se pkt.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 120 mg of denosumab in 1.7 mL of solution (70 mg/mL).
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hvert hætteglas indeholder 120 mg denosumab i 1,7 ml injektionsvæske (70 mg/ml).
English: NR NR NR NR NR 28.6
Danish: IN IN IN IN IN 28,6
English: If you become pregnant during treatment with XGEVA or less than 5 months after stopping treatment with XGEVA, please inform your doctor.
Danish: Fortæl det til lægen, hvis du bliver gravid, mens du er i behandling med XGEVA eller inden for 5 måneder efter behandlingen med XGEVA er stoppet.
English: Cases of osteonecrosis of the jaw (see sections 4.4 and section 4.8 - description of selected adverse reactions) have been commonly observed in patients taking XGEVA.
Danish: 4.8 - beskrivelse af udvalgte bivirkninger) med frekvensen almindelig hos patienter, der fik XGEVA.
English: • removal of a tooth,
Danish: • tandudtrækning,
English: Efficacy and safety of 120 mg XGEVA SC every 4 weeks or 4 mg zoledronic acid (dose-adjusted for reduced renal function) IV every 4 weeks were compared in three randomised, double-blind,
Danish: Virkningen og sikkerheden af 120 mg XGEVA s.c. hver 4. uge eller 4 mg zoledronsyre i.v.
English: Proportion of subjects without SRE
Danish: Andel patienter uden KRH
English: A grade 3 decrease in serum calcium levels was experienced in 2.5% of patients treated with XGEVA and 1.2% of patients treated with zoledronic acid.
Danish: En grad 3 reduktion i serum calciumniveauet forekom hos 2,5% af patienterne, der blev behandlet med XGEVA, og hos 1,2% af patienterne, der blev behandlet med zoledronsyre.
English: In patients whose disease is controlled by XGEVA, the effect of interruption or cessation of treatment has not been evaluated, however limited data in these patients does not indicate a rebound effect upon cessation of treatment.
Danish: Begrænsede data fra disse patienter tyder dog ikke på en rebound-effekt ved seponering af behandlingen.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 1.7 mL
Danish: INDHOLD ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER
English: If hypocalcaemia occurs while receiving XGEVA, additional calcium supplementation and additional monitoring may be necessary.
Danish: Yderligere tilskud af calcium og yderligere monitorering kan være nødvendig, hvis der opstår hypokalcæmi i forbindelse med behandling med XGEVA.
English: NAME OF THE MEDICINAL PRODUCT XGEVA 120 mg solution for injection
Danish: LÆGEMIDLETS NAVN XGEVA 120 mg injektionsvæske, opløsning
English: How to store XGEVA
Danish: Sådan skal du bruge XGEVA
English: What XGEVA is and what it is used for What you need to know before you use XGEVA How to use XGEVA
Danish: Det skal du vide, før du begynder at bruge XGEVA Sådan skal du bruge XGEVA Bivirkninger
English: A grade 4 decrease in serum calcium levels was experienced in 0.6% of patients treated with XGEVA and 0.2% of patients treated with zoledronic acid (see section 4.4).
Danish: En grad 4 reduktion i serum calciumniveauet forekom hos 0,6% af patienterne, der blev behandlet med XGEVA, og hos 0,2% af patienterne, der blev behandlet med zoledronsyre (se pkt.
English: A higher incidence of ONJ among subjects treated with denosumab compared to zoledronic acid has been observed in SRE prevention clinical trials.
Danish: I kliniske studier af forebyggelse af KRH'er er der observeret en højere incidens af ONJ blandt patienter i behandling med denosumab sammenlignet med zoledronsyre.
English: NAME OF THE MEDICINAL PRODUCT XGEVA 120 mg solution for injection denosumab
Danish: LÆGEMIDLETS NAVN XGEVA 120 mg injektionsvæske, opløsning denosumab
English: Hazard ratio (95% CI) NE = not estimable
Danish: Overall survival Hazard ratio (95% CI) IE = ikke estimérbar HCM = hyperkalcæmi af malignitet
English: A grade 4 decrease in serum calcium levels was experienced in 0.4% of patients treated with XGEVA and 0.1% of patients treated with zoledronic acid.
Danish: En grad 4 reduktion i serum calciumniveauet forekom hos 0,4% af patienterne, der blev behandlet med XGEVA, og hos 0,1% af patienterne, der blev behandlet med zoledronsyre.
English: In the post-marketing setting, severe symptomatic hypocalcaemia (including fatal cases) has been reported, with most cases occurring in the first weeks of initiating therapy.
Danish: Efter markedsføring af præparatet er der indberettet alvorlig, symptomatisk hypokalcæmi (herunder dødelige tilfælde).
English: XGEVA contains denosumab, a protein (monoclonal antibody) that works to slow down bone destruction caused by cancer spreading to the bone (bone metastasis) or by giant cell tumour of bone.
Danish: XGEVA indeholder denosumab, som er et protein (et monoklonalt antistof).
English: A higher incidence of hypocalcaemia among subjects treated with denosumab compared to zoledronic acid has been observed in SRE prevention clinical trials.
Danish: I kliniske studier af forebyggelse af KRH'er (knoglerelaterede hændelser) er der observeret en højere incidens af hypokalcæmi blandt patienter i behandling med denosumab sammenlignet med zoledronsyre.
English: A grade 3 decrease in serum calcium levels was experienced in 1.4% of patients treated with XGEVA and 0.6% of patients treated with zoledronic acid.
Danish: En grad 3 reduktion i serum calciumniveauet forekom hos 1,4% af patienterne, der blev behandlet med XGEVA, og hos 0,6% af patienterne, der blev behandlet med zoledronsyre.
English: Osteonecrosis of the jaw1
Danish: Osteonekrose i kæben1
English: If you are nursing during treatment with XGEVA, please inform your doctor.
Danish: Fortæl det til lægen, hvis du ammer, mens du er i behandling med XGEVA.
English: Osteonecrosis of the external auditory canal
Danish: Osteonekrose i ydre øregang
English: No dose adjustment is required in patients with renal impairment (see section 4.4 for recommendations relating to monitoring of calcium, 4.8 and 5.2).
Danish: 4.4 for anbefalinger vedrørende monitorering af calcium samt pkt.
English: HR (95% CI) / RRR (%)
Danish: Hyppighedsratio (95% CI)/RRR
English: In order to reduce the risk of developing osteonecrosis of the jaw, there are some precautions you should take:
Danish: Der er nogle forsigtighedsregler, du skal følge for at mindske risikoen for, at du får osteonekrose i kæben.
English: • shortness of breath,
Danish: • stakåndethed,
English: Study Month
Danish: Studiemåned
English: Tell your doctor if you have or have had severe kidney problems, kidney failure or have needed dialysis, which may increase your risk of getting low blood calcium, especially if you do not take calcium supplements.
Danish: Fortæl det til din læge, hvis du har eller har haft alvorlige nyreproblemer, nyresvigt eller behov for dialyse.
English: The most common adverse reactions with XGEVA are musculoskeletal pain.
Danish: Faldene i serumcalcium kunne generelt behandles med tilskud af calcium og vitamin D. De mest almindelige bivirkninger efter behandling med XGEVA er muskuloskeletale smerter.
English: SMR per Year
Danish: P-værdi for superioritet KMR pr. år
English: Clear, colourless to slightly yellow solution and may contain trace amounts of translucent to white proteinaceous particles.
Danish: Injektionsvæsken kan indeholde spormængder af gennemsigtige til hvide proteinlignende partikler.
English: In the post-marketing setting, severe symptomatic hypocalcaemia (including fatal cases) has been reported (see section 4.8), with most cases occurring in the first weeks of initiating therapy, but can occur later.
Danish: Efter markedsføring af præparatet er der indberettet alvorlig, symptomatisk hypokalcæmi (herunder dødelige tilfælde) (se pkt.
English: Unusual thigh bone fractures
Danish: Usædvanlige brud i lårbenet
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 08/07/2005
Danish: DATO FOR FØRSTE TILLADELSE/FORNYELSE AF TILLADELSEN Dato for første markedsføringstilladelse: 08/07/2005
English: A third vaccination with Equilis Te should be repeated at least four weeks later.
Danish: En tredje vaccination med Equilis Te bør gentages mindst 4 uger senere.
English: 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Danish: 4.10 Overdosering (symptomer, nødforanstaltninger, modgift) om nødvendigt
English: 42 months
Danish: 30 måneder
English: Pharmacotherapeutic group: Inactivated bacterial vaccine.
Danish: Farmakoterapeutisk gruppe: Inaktiveret bakteriel vaccine.
English: Following the administration of a double dose of vaccine, no side effects other than those described under section 4.6 have been observed except for some depression at the day of vaccination.
Danish: Efter administration af en dobbelt vaccinedosis er der ikke set andre bivirkninger end dem, der er beskrevet under afsnit 4.6, bortset fra nogen nedstemthed på vaccinationsdagen.
English: ATC vet code: QI05AB03
Danish: ATCvet-kode: Q105AB03
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/ ).
Danish: Yderligere information om dette lægemiddel er tilgængelig på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu
English: 375 µg
Danish: 375 μg
English: Date of last renewal: 10/06/2015
Danish: Dato for seneste fornyelse af markedsføringstilladelse: 10/06/2015
English: 125 µg
Danish: 125 μg
English: THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE
Danish: TEKSTEN “KUN TIL DYR” SAMT BETINGELSER ELLER BEGRÆNSNINGER FOR UDLEVERING OG BRUG, OM NØDVENDIGT
English: The first revaccination is given not later than 17 months after the primary vaccination course.
Danish: Den første revaccination gives ikke senere end 17 måneder efter grundvaccinationen.
English: Special precautions for use in animals: Only healthy animals should be vaccinated.
Danish: Special forholdsregler til brug hos dyr: Kun raske dyr bør vaccineres.
English: Emil-von-Behring-Str. 76 35 041 Marburg Germany
Danish: GSK Vaccines GmbH Emil-von-Behring-Str. 76 35041 Marburg Tyskland
English: Administer 1 ml of vaccine intramuscularly.
Danish: Indgiv 1 ml vaccine intramuskulært.
English: 24 months after the first revaccination
Danish: 24 måneder efter den første revaccination
English: PACKAGE SIZE 10 x 1 dose
Danish: 10 x 1 dosis
English: Foals should not be vaccinated before the age of 6 months, especially when born to mares that were revaccinated in the last two months of gestation, because of possible interference by maternally derived antibodies.
Danish: Føl bør ikke vaccineres, før de er 6 måneder gamle, især ikke hvis hoppen blev revaccineret i de sidste to måneder af drægtigheden, da der er risiko for interferens med maternelt overførte antistoffer.
English: A clear opalescent suspension.
Danish: Klar opaliserende suspension.
English: Vaccination schedule: Primary vaccination course
Danish: Vaccinationsprogram: Grundvaccination
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 1 ml vial and 1 ml pre-filled syringe
Danish: MINDSTEKRAV TIL OPLYSNINGER PÅ SMÅ INDRE PAKNINGER 1 ml hætteglas og 1 ml præfyldte sprøjter
English: STATEMENT OF ACTIVE AND OTHER SUBSTANCES Tetanus toxoid 40 Lf/ml
Danish: Tetanus toksoid 40 Lf/ml
English: 4.7 Use during pregnancy, lactation or lay
Danish: 4.7 Anvendelse under drægtighed, laktation
English: Active immunisation of horses from 6 months of age against tetanus to prevent mortality.
Danish: Aktiv immunisering af heste fra 6 måneders alderen mod stivkrampe for at forhindre dødelighed.
English: 4.3 Contraindications None.
Danish: 4.3 Kontraindikationer
English: 1 Flocculation equivalents; corresponds with ≥ 30 IU/ml guinea pig serum in the Ph. Eur.
Danish: 1 Flokkulations ækvivalenter; svarende til ≥ 30 IE/ml marsvineserum i Ph.Eur.
English: In that case, the first dose (V1) of vaccine can be given concurrently with the appropriate prophylactic dose of Tetanus-Serum at a separate injection site, using separate syringes and needles.
Danish: I sådanne tilfælde kan første vaccinedosis (V1) gives samtidigt med en behørig profylaktisk dosis af tetanusserum på et andet injektionssted og ved brug af separate sprøjter og kanyler.
English: Administer one dose (1ml), by intramuscular injection, according to the following schedule: • Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later
Danish: Indgiv en dosis (1 ml) ved intramuskulær injektion efter følgende program: • Grundvaccination: Første vaccination fra 6 måneders alderen, anden vaccination 4 uger senere.
English: The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) 470/2009.
Danish: Aktiv substans som principielt er af biologisk oprindelse hvis formål er at producere aktivimmunitet falder ikke indenfor anvendelsesområdet af Forordning (EF) nr. 470/2009 når det anvendes som i dette veterinære lægemiddel.
English: 1 ml suspension in type I glass pre-filled syringe, containing a plunger with a halogenobutyl end and closed with a halogenobutyl stopper.
Danish: 1 ml suspension i præfyldte sprøjter af glas (type I), indeholdende et stempel med en top af halogenobutyl og lukket med en prop af halogenobutyl.
English: In case of increased infection risk or insufficient colostrum intake, an additional initial injection can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 6 months of age and 4 weeks later)
Danish: I tilfælde af øget smitterisiko eller utilstrækkelig indtagelse af råmælk, kan der gives en ekstra vaccination ved 4 måneders alderen efterfulgt af et fuldt grundvaccinationsforløb (vaccination ved 6 måneders alderen og 4 uger senere).
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental self-injection, seek medical advice immediately and show this package insert or the label to the physician.
Danish: Særlige forsigtighedsregler for personer, som indgiver lægemidlet til dyr I tilfælde af selvinjektion ved hændeligt uheld skal der straks søges lægehjælp, og indlægssedlen eller etiketten bør vises til lægen.
English: To stimulate active immunity against tetanus.
Danish: IMMUNOLOGISKE EGENSKABER Til stimulering af aktiv immunitet mod tetanus
English: Duration of immunity:
Danish: Immuniteten varer:
English: 1 ml suspension in type I glass vial closed with a halogenobutyl rubber stopper and sealed with an aluminium cap.
Danish: 1 ml suspension i hætteglas (type I), lukket med en halogenobutyl gummiprop og forseglet med en aluminiums hætte.
English: This will lead to a passive protection against tetanus for at least 21 days after concurrent administration.
Danish: Den samtidige administration vil give passiv beskyttelse mod tetanus i mindst 21 dage.
English: Intervet International B.V. NL-5831 AN Boxmeer
Danish: NL-5831 AN Boxmeer
English: To be supplied only on veterinary prescription.
Danish: Veterinærlægemidlet må kun udleveres efter veterinærrecept.
English: Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Tetanus Serum from Intervet (see section 8).
Danish: Der foreligger oplysninger om sikkerhed og virkning, som viser, at vaccinen kan gives samme dag som, men ikke blandet med tetanusserum (se afsnit 8).
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box with 10 vials
Danish: OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE Karton æske med 10 hætteglas
English: Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Tetanus Serum from Intervet.
Danish: Der foreligger oplysninger om sikkerhed og virkning, som viser, at vaccinen kan gives samme dag som, men ikke blandet med tetanusserum fra Intervet.
English: THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN" Keep out of the sight and reach of children.
Danish: TEKSTEN “OPBEVARES UTILGÆNGELIGT FOR BØRN” Opbevares utilgængeligt for børn.
English: The vaccine can be used together with Tetanus-Serum for treatment of injured horses that have not been immunised against tetanus.
Danish: Vaccinen kan anvendes sammen med tetanusserum til behandling af tilskadekomne heste, der ikke er blevet immuniseret mod tetanus.
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each dose of 1 ml contains:
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER OG HJÆLPESTOFFER Hver dosis af 1 ml indeholder:
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Equilis Te suspension for injection for horses
Danish: VETERINÆRLÆGEMIDLETS NAVN Equilis Te, injektionsvæske, suspension til heste
English: Onset of immunity:
Danish: Immuniteten indtræder:
English: 4.5 Special precautions for use Special precautions for use in animals
Danish: 4.5 Særlige forsigtighedsregler vedrørende brugen
English: Equilis Te [a clear pictogram of a horse]
Danish: VETERINÆRLÆGEMIDLETS NAVN Equilis Te [piktogram af en hest]
English: 2 weeks after the primary vaccination course
Danish: 2 uger efter grundvaccination
English: A diffuse hard or soft swelling (max. diameter 5 cm) may rarely occur at the injection site, regressing within 2 days.
Danish: 5 cm i diameter) kan i sjældne tilfælde opstå på injektionsstedet, men forsvinder inden for 2 døgn.
English: EXP {month/year}
Danish: Udløbsdato{måned/år}
English: Name and address of the manufacturers of the biological active substance GSK Vaccines GmbH
Danish: Navn og adresse på fremstillerne af det biologisk aktive stof
English: Cardboard box with 10 pre-filled syringes with needles
Danish: Karton æske med 10 præfyldte sprøjter med nåle
English: Cardboard box with 10 glass vials.
Danish: Kartonæske med 10 hætteglas.
English: Concurrent use of Equilis Te and Tetanus-Serum from Intervet may reduce active immunity against tetanus compared to horses vaccinated with Equilis Te in the absence of tetanus antitoxin serum.
Danish: Samtidig anvendelse af Equilis Te og tetanusserum fra Intervet kan reducere den aktive immunitet mod tetanus sammenlignet med heste, der er vaccineret med Equilis Te men ikke har fået tetanus antitoksinserum.
English: Purified Saponin
Danish: Adjuvans: Renset Saponin